Patent application number | Description | Published |
20100003256 | Use of TGF-Beta Antagonists in Treatment of Parathyroid-Related Disorders - The present invention relates to the use of TGF-β antagonists for the treatment, amelioration, and diagnosis of parathyroid-related disorders, e.g., HPT-JT, familial isolated primary hyperparathyroidism (FIPH), and hyperparathyroidism-jaw tumor (HPT-JT) syndrome, as well as its attendant complications. The present invention also relates to the use of modulators of HRPT2 and its related PAF1 complex for the treatment, amelioration, and diagnosis of TGFβ-related disorders, e.g., pulmonary hypertension, cancer, hypertension, fibrosis, wound healing. Assays of the identification of modulators of HRPT2/PAF1 and SMAD/TGFβ are also provided. | 01-07-2010 |
20100272734 | COMPOSITIONS AND METHODS FOR INCREASING MUSCLE GROWTH - This disclosure is in the field of anti-Activin receptor IIB (ActRIIB) antibodies. In particular, it relates to the use of said antibodies for treating muscle disorders, such as muscle wasting due to disease or disuse. | 10-28-2010 |
20120003219 | Compositions and Methods to Treat Bone Related Disorders - The present invention relates to the use of modulators of the sclerostin:sclerostin-binding-partner interaction for the treatment, amelioration, and diagnosis of sclerostin-related disorders, e.g., osteoporosis and sclerosteosis, and sclerostin-related disorders, e.g., cancers and cardiovascular disorders. The invention also relates to the use of sclerostin-binding-partner mimetics for the treatment, amelioration, and diagnosis of sclerostin-related disorders. Assays for the identification of modulators of the sclerostin:sclerostin-binding-partner interaction, as well as the resulting signaling, are also provided. | 01-05-2012 |
20130164284 | COMPOSITIONS AND METHODS TO TREAT BONE RELATED DISORDERS - The present invention relates to the use of modulators of the sclerostin: sclerostin-binding-partner interaction for the treatment, amelioration, and diagnosis of sclerostin-related disorders, e.g., osteoporosis and sclerosteosis, and sclerostin-related disorders, e.g., cancers and cardiovascular disorders. The invention also relates to the use of sclerostin-binding-partner mimetics for the treatment, amelioration, and diagnosis of sclerostin-related disorders. Assays for the identification of modulators of the sclerostin: sclerostin-binding-partner interaction, as well as the resulting signaling, are also provided. | 06-27-2013 |
Patent application number | Description | Published |
20090175794 | INHIBITORS OF CARBONIC ANHYDRASE IX - Novel radiopharmaceuticals that are useful in diagnostic imaging and therapeutic treatment of disease characterized by over expression of CA-IX comprise a complex that contains a sulfonamide moiety which is capable of binding the active catalytic site of CA-IX, and a radionuclide adapted for radioimaging and/or radiotherapy: | 07-09-2009 |
20090281088 | BICYCLIC NITROIMIDAZOLE-SUBSTITUTED PHENYL OXAZOLIDINONES - The current invention provides a series of bicyclic nitroimidazole-substituted phenyl oxazolidinones in which a bicyclic nitroimidazole pharmacophore is covalently bonded to a phenyl oxazolidinone, their pharmaceutical compositions, and the method of use of the compositions for prevention and treatment of bacterial infections. The bicyclic nitroimidazole-substituted phenyl oxazolidinones possess surprising antibacterial activity against wild-type and resistant strains of pathogens, and are therefore useful for the prevention, control and treatment of a number of human and veterinary bacterial infections caused by these pathogens, such as | 11-12-2009 |
20100178246 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF FOR INHIBITING PSMA - A compound of Formula I, a pharmaceutically acceptable salt, or solvate thereof: | 07-15-2010 |
20100178247 | CA-IX SPECIFIC RADIOPHARMACEUTICALS FOR THE TREATMENT AND IMAGING OF CANCER - A compound that recognizes and binds to the CA-IX protein has Formula I, II, III, or IV. The compounds may include a radioactive element for radioimaging or therapeutic applications. Thus, pharmaceutical compositions may be prepared with one or more of the compounds of Formula I, II, III, or IV. | 07-15-2010 |
20100183509 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF - Complexes of heterocyclic radionuclides are prepared based upon ligands having substituted pyridyl and imidazolyl groups. The ligands are bifunctional, having amino acid residues that may act as a linker to a bioactive molecule, and a tridentate chelator that may complex the radionuclide. The bioactive molecule may be a peptide or somatostatin. | 07-22-2010 |
20130034494 | RADIOLABELED PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS - Compounds according to Formula I and Formula II are potent inhibitors of PSMA activity: | 02-07-2013 |
20130216477 | METAL COMPLEXES OF POLY(CARBOXYL)AMINE-CONTAINING LIGANDS HAVING AN AFFINITY FOR CARBONIC ANHYDRASE IX - The present invention is directed to CA IX inhibitors that conform to Formula I where the substituents X, A, B, D, E, E′ and G are as defined above. | 08-22-2013 |
20140179902 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF - Complexes of heterocyclic radionuclides are prepared based upon ligands having substituted pyridyl and imidazolyl groups. The ligands are bifunctional, having amino acid residues that may act as a linker to a bioactive molecule, and a tridentate chelator that may complex the radionuclide. The bioactive molecule may be a peptide or somatostatin. | 06-26-2014 |
20140255306 | TRIAZINE BASED RADIOPHARMACEUTICALS AND RADIOIMAGING AGENTS - Compounds according to Formula I and Formula II are potent inhibitors of PSMA. | 09-11-2014 |
20140341805 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF - A method of imaging a region in a subject includes administering to the subject a complex of a metal chelated to a compound, and obtaining an image of the region in the subject. | 11-20-2014 |
20150078998 | RADIOLABELED PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS - Compounds according to Formula I and Formula II are potent inhibitors of PSMA activity: | 03-19-2015 |
Patent application number | Description | Published |
20110263128 | SELECTIVE WET ETCHING AND TEXTURED SURFACE PLANARIZATION PROCESSES - The present invention relates to systems and methods associated with selective wet etching and textured surface planarization. The systems and methods described herein can be used to etch a component of a multi-layer stack, such as a GaN layer. In some embodiments, the multi-layer stack can include a substrate having a patterned surface and a light generating region. The substrate can be removed from the first multi-layer stack to form a second multi-layer stack. In some embodiments, the pattern on the surface of the substrate can leave behind a pattern on a surface of the second multi-layer stack. Accordingly, in some cases, the surface of the second multi-layer stack can be wet etched, for example, to smoothen the surface. In some embodiments, removing the substrate can expose an N-face of a GaN layer, and the wet etch can be performed such that the N-face of the GaN layer is etched. In some embodiments, the multi-layer stack includes a light generating region and can be part of a light emitting device. | 10-27-2011 |
20120261711 | ELECTRONIC DEVICE CONTACT STRUCTURES - Electronic devices involving contact structures, and related components, systems and methods associated therewith are described. The contact structures are particularly suitable for use in a variety of light-emitting devices, including LEDs. | 10-18-2012 |
20130017634 | WAVELENGTH CONVERTING LIGHT-EMITTING DEVICES AND METHODS OF MAKING THE SAME - Wavelength converting light-emitting devices and methods of making the same are provided. In some embodiments, the devices include a phosphor material region designed to convert the wavelength of emitted light. | 01-17-2013 |
Patent application number | Description | Published |
20080214470 | Pin1-Modulating Compounds and Methods of Use Thereof - The invention is directed to peptide modulators of Pin1 and Pin1-related proteins and the use of such modulators for treatment of Pin1 associated states, e.g., for the treatment of cancer or neurodegenerative disease. | 09-04-2008 |
20090258352 | Pin1 as a marker for abnormal cell growth - Methods for the use of Pin1 as a marker of abnormal cell growth are disclosed. In one embodiment, the method includes detecting a level of Pin1 to stage an abnormal cell growth, such as breast or prostate cancer. In another embodiment, the method includes evaluating the efficacy of a treatment of an abnormal cell growth, such as cancer, by monitoring the levels of Pin1. In another embodiment, the method includes evaluating the extent of metastasis of abnormal cell growth, such as cancer. The levels of Pin1 can be protein levels or nucleic acid levels. | 10-15-2009 |
20130028900 | METHODS AND COMPOSITIONS FOR THE GENERATION AND USE OF CONFORMATION-SPECIFIC ANTIBODIES - The present invention features methods and compositions for the generation and use of conformation-specific anti-bodies or fragments thereof. | 01-31-2013 |
20140086909 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS - The invention features methods of treating a proliferative disorder characterized by elevated Pin1 marker levels and/or reduced Pin1 Ser71 phosphorylation in a subject by administering a retinoic acid compound. Additionally, the invention features methods of treating proliferative disorders (e.g., proliferative disorders characterized by elevated Pin1 marker levels) by administering a retinoic acid compound in combination with another anti-proliferative compound. Finally, the invention also features methods including high-throughput screens for discovering and validating Pin1 inhibitors. | 03-27-2014 |
20140219957 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF IMMUNE DISORDERS - The invention features methods of treating an immune disorder characterized by elevated Pin1 marker levels in a subject by administering a retinoic acid compound. Additionally, the invention features methods of treating immune disorders (e.g., immune disorders characterized by elevated Pin1 marker levels) by administering a retinoic acid compound in combination with an anti-inflammatory, anti-viral, or anti-microbial compound. | 08-07-2014 |
20140242100 | METHODS AND COMPOSITIONS FOR THE GENERATION AND USE OF CONFORMATION-SPECIFIC ANTIBODIES - The present invention features methods and compositions for the generation of conformation-specific antibodies. | 08-28-2014 |
20150038683 | METHODS AND COMPOSITIONS FOR THE GENERATION AND USE OF CONFORMATION-SPECIFIC ANTIBODIES - The present invention features methods and compositions for the generation and use of conformation-specific antibodies or fragments thereof. | 02-05-2015 |
20150044278 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS - The invention features methods of treating a proliferative disorder characterized by elevated Pin1 marker levels and/or reduced Pin1 Ser71 phosphorylation in a subject by administering a retinoic acid compound. Additionally, the invention features methods of treating proliferative disorders (e.g., proliferative disorders characterized by elevated Pin1 marker levels) by administering a retinoic acid compound in combination with another anti-proliferative compound. Finally, the invention also features methods including high-throughput screens for discovering and validating Pin1 inhibitors. | 02-12-2015 |
Patent application number | Description | Published |
20130090371 | METHODS AND COMPOSITIONS FOR INHIBITION OF BETA2-ADRENERGIC RECEPTOR DEGRADATION - The present invention generally relates to compositions and kits comprising a β2-AR agonist and a modulator of a β2-AR regulator gene, where the modulator of the β2-AR regulator gene inhibits the internalization and/or degradation of the β2-ad-renergic receptor (β2-AR). More specifically, the present invention relates to the use of an agonist of β2-adrenergic receptor (β2-AR) and an agent which inhibits agonist induced β2-adrenergic receptor (β2-AR) internalization and/or degradation in method for the treatment of a respiratory disorder in a subject. | 04-11-2013 |
20150037421 | ARRDC1-MEDIATED MICROVESICLES (ARMMS) AND USES THEREOF - The invention provide isolated arrestin domain-containing protein 1 (ARRDC1)-mediated micro vesicles (ARMMs). Methods for generating and for isolating ARMMs are also provided herein. ARMMs can be used to deliver agents, for example, nucleic acids (e.g., siRNAs, microRNAs, lincRNAs), proteins (e.g., transcription factors, chromatin modulators, kinases, phosphorylases, or recombinases), or small molecules to target cells in vitro and in vivo, and methods for such ARMM-mediated delivery are provided herein. Diagnostic and therapeutic methods using ARMMs are also described herein. | 02-05-2015 |
Patent application number | Description | Published |
20090053256 | Poxvirus Methods And Compositions - Methods and compositions for inducing immune responses against poxviruses are disclosed. The compositions include nucleic acids that encode modified vaccinia and variola antigens. Compositions that include recombinant vaccinia and variola polypeptides are also disclosed. | 02-26-2009 |
20090098144 | IMMUNOGEN PRESENTING HIV GP120 V3 LOOP IN A CONFORMATION THAT INDUCES BROADLY NEUTRALIZING ANTIBODIES - Insertion of HIV-1 V3 loop peptides from the viral glycoprotein gp120 into selected, immunogenic scaffold proteins results in a recombinant polypeptide that is a potent V3 immunogen. V3 immunogens include natural and consensus V3 sequences and cyclic and reverse peptides. Preferred scaffold proteins are Cholera Toxin subunit B and homologues thereof including closely related | 04-16-2009 |
20090291472 | INFLUENZA NUCLEIC ACIDS, POLYPEPTIDES, AND USES THEREOF - Codon-optimized nucleic acids encoding influenza polypeptides and uses of the nucleic acids and polypeptides for inducing immune responses are provided herein. | 11-26-2009 |
20110171258 | POLYVALENT, PRIMARY HIV-1 GLYCOPROTEIN DNA VACCINES AND VACCINATION METHODS - Polyvalent, primary isolate nucleic acid compositions for inducing an immune response against HIV is disclosed. The compositions and methods described herein are for the use of a DNA composition that encodes one or more different HIV envelope glycoproteins. The DNA composition can encode an HIV Gag protein. The DNAs encoding one or more HIV proteins are a combination of different nucleic acids, such as DNA plasmids, generated from primary isolate DNA of different HIV major group genetic clades and/or different proteins. HIV protein compositions for inducing an immune response against HIV are disclosed. Methods for using the protein compositions as boosts following administration of the DNA compositions are provided. | 07-14-2011 |
20130287804 | IMMUNOGENIC POLYPEPTIDES HAVING AN IMMUNOGENIC SCAFFOLD PROTEIN AND A LOOP PEPTIDE, PRESENTING A 3074- OR 2219/2557- MONOCLONAL ANTIBODY-TARGETED EPITOPE, WHICH IS PRESENT IN THE HIV GP120 PROTEIN - The present invention is directed to a recombinant immunogenic polypeptide. The polypeptide includes a loop peptide inserted into an immunogenic scaffold protein. The loop polypeptide has an amino acid sequence which presents the 3074 mAb- or the 2219/2557 mAb-targeted epitope of the HIV gp120 protein and not other known epitopes of the HIV gp120 protein. When used as an immunogen, the polypeptide induces an antibody response which neutralizes heterologous HIV-1 viruses in a pattern similar to that observed for the 3074 mAb- or the 2219/2557 mAb-targeted epitope, respectively. Pharmaceutical compositions containing the immunogenic polypeptide as well as methods of making and using it are also disclosed. | 10-31-2013 |
Patent application number | Description | Published |
20110064705 | HEMANGIO COLONY FORMING CELLS AND NON-ENGRAFTING HEMANGIO CELLS - Methods of generating and expanding human hemangio-colony forming cells and non-engrafting hemangio cells in vitro and methods of expanding and using such cells are disclosed. The methods permit the production of large numbers of hemangio-colony forming cells, non-engrafting hemangio cells as well as derivative cells, such as hematopoietic and endothelial cells. The cells obtained by the methods disclosed may be used for a variety of research, clinical, and therapeutic applications. Human non-engrafting hemangio cells are a novel progenitor cell population that is related to but distinct from the hemangioblast and human hemangio-colony forming cells. The invention also provides compositions, preparations, and solutions comprising hemangio-colony forming cells, non-engrafting hemangio cells or cells differentiated therefrom. The compositions, preparations, and solutions include cryopreserved preparations and substantially purified preparations, as well as mixed compositions formulated in combination with related hemangioblast progenitor cell types that can engraft into the bone marrow. | 03-17-2011 |
20110086424 | METHODS FOR PRODUCING ENUCLEATED ERYTHROID CELLS DERIVED FROM PLURIPOTENT STEM CELLS - Methods for generating enucleated erythroid cells using pluripotent stem cells are provided. The methods permit the production of large numbers of cells. The cells obtained by the methods disclosed may be used for a variety of research, clinical, and therapeutic applications. Methods for generating megakaryocyte and platelets are also provided. | 04-14-2011 |
20110171185 | Genetically intact induced pluripotent cells or transdifferentiated cells and methods for the production thereof - The present disclosure relates to methods for dedifferentiating and transdifferentiating recipient cells, preferably human somatic cells. These methods minimize the risk of undesired genome sequence alteration. These methods employ reprogramming factors, which may be used alone or in certain combinations with one another. These methods have application especially in the context of cell-based therapies, establishment of cell lines, and the production of genetically modified cells. | 07-14-2011 |
20110286978 | Genetically Intact Induced Pluripotent Cells Or Transdifferentiated Cells And Methods For The Production Thereof - The present disclosure relates to methods for dedifferentiating and transdifferentiating recipient cells, preferably human somatic cells. These methods minimize the risk of undesired genome sequence alteration. These methods employ reprogramming factors, which may be used alone or in certain combinations with one another. These methods have application especially in the context of cell-based therapies, establishment of cell lines, and the production of genetically modified cells. | 11-24-2011 |
20120027731 | HEMANGIO-COLONY FORMING CELLS - Methods of generating and expanding human hemangio-colony forming cells in vitro and methods of expanding and using such cells are disclosed. The methods permit the production of large numbers of hemangio-colony forming cells as well as derivative cells, such as hematopoietic and endothelial cells. The cells obtained by the methods disclosed may be used for a variety of research, clinical, and therapeutic applications. | 02-02-2012 |
20120282693 | METHOD OF GENERATING NATURAL KILLER CELLS AND DENDRITIC CELLS FROM HUMAN EMBRYONIC STEM CELL-DERIVED HEMANGIOBLASTS - This invention provides methods of generating natural killer (NK) cells and dendritic cells (DCs). The methods utilize human hemangioblasts as intermediate cells to generate the NK cells and DCs. In various embodiments, the methods do not require the use of stromal feeder layers. | 11-08-2012 |
20120315338 | LARGE SCALE GENERATION OF FUNCTIONAL MEGAKARYOCYTES AND PLATELETS FROM HUMAN EMBRYONIC STEM CELLS UNDER STROMAL-FREE CONDITIONS - The present invention provides a method of generating megakaryocytes and platelets. In various embodiments, method involves the use of human embryonic stem cell derived hemangioblasts for differentiation into megakaryocytes and platelets under serum and stromal-free condition. In this system, hESCs are directed towards megakaryocytes through embryoid body formation and hemangioblast differentiation. Further provided is a method of treating a subject in need of platelet transfusion. | 12-13-2012 |
20140271590 | METHODS FOR PRODUCTION OF PLATELETS FROM PLURIPOTENT STEM CELLS AND COMPOSITIONS THEREOF - Methods for production of platelets from pluripotent stem cells, such as human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) are provided. These methods may be performed without forming embryoid bodies or clusters of pluripotent stem cells, and may be performed without the use of stromal inducer cells. Additionally, the yield and/or purity can be greater than has been reported for prior methods of producing platelets from pluripotent stem cells. Also provided are compositions and pharmaceutical preparations comprising platelets, preferably produced from pluripotent stem cells. | 09-18-2014 |
20140294778 | PHOTORECEPTORS AND PHOTORECEPTOR PROGENITORS PRODUCED FROM PLURIPOTENT STEM CELLS - Methods are provided for the production of photoreceptor cells and photoreceptor progenitor cells from pluripotent stem cells. Additionally provided are compositions of photoreceptor cells and photoreceptor cells, as well as methods for the therapeutic use thereof. Exemplary methods may produce substantially pure cultures of photoreceptor cells and/or photoreceptor cells. | 10-02-2014 |
20140370007 | METHOD OF DIRECTED DIFFERENTIATION PRODUCING CORNEAL ENDOTHELIAL CELLS, COMPOSITIONS THEREOF, AND USES THEREOF - This disclosure generally relates to cell-based therapies for treatment of visual disorders, including disorders of the cornea. Methods are exemplified for directed differentiation of corneal cells from stem cells. Compositions of corneal endothelial cells and uses thereof are also provided. Exemplary compositions exhibit improved cell density and/or more “youthful” gene expression relative to cells obtained from donated tissue. | 12-18-2014 |
Patent application number | Description | Published |
20110097721 | IN VIVO GENE SENSORS - Described are methods and compositions for the detection of target genes. The inventors have developed a synthetic nucleic acid sensor-effector gene circuit. In cells without a target gene, the circuit suppresses e.g., effector production, but in the presence of the target gene the suppression is subject to competition, such that the synthetic sensor is de-repressed and permits expression of the effector gene. The methods and compositions described further permit the selective expression of an effector gene in those cells expressing the target gene. In this manner, cells expressing a target gene can be selectively targeted for treatment or elimination. In certain aspects, the methods and compositions described permit the selective expression of an agent such as a therapeutic gene product, in a specifically targeted population of cells in an organism. | 04-28-2011 |
20130009799 | BIOLOGICAL ANALOG-TO-DIGITAL AND DIGITAL-TO-ANALOG CONVERTERS - Described herein are novel biological converter switches that utilize modular components, such as genetic toggle switches and single invertase memory modules (SIMMs), for converting analog inputs to digital outputs, and digital inputs to analog outputs, in cells and cellular systems. Flexibility in these biological converter switches is provided by combining individual modular components, i.e., SIMMs and genetic toggle switches, together. These biological converter switches can be combined in a variety of network topologies to create circuits that act, for example, as switchboards, and regulate the production of an output product(s) based on the combination and nature of input signals received. | 01-10-2013 |
20140178864 | MODULAR NUCLEIC ACID-BASED CIRCUITS FOR COUNTERS, BINARY OPERATIONS, MEMORY, AND LOGIC - We have created novel engineered genetic counter designs and methods of use thereof that utilize DNA recombinases to provide modular systems, termed single invertase memory modules (SIMMs), for encoding memory in cells and cellular systems. Our designs are easily extended to compute to high numbers, by utilizing the >100 known recombinases to create subsequent modules. Flexibility in our engineered genetic counter designs is provided by daisy-chaining individual modular components, i.e., SIMMs together. These modular components of the engineered genetic counters can be combined in other network topologies to create circuits that perform, amongst other things, logic and memory. Our novel engineered genetic counter designs allow for the maintenance of memory and provide the ability to count between discrete states by expressing the recombinases between their cognate recognition sites. | 06-26-2014 |
Patent application number | Description | Published |
20120301433 | BACTERIOPHAGES EXPRESSING AMYLOID PEPTIDES AND USES THEREOF - The present invention generally relates to engineered bacteriophages which express amyloid peptides for the modulation (e.g. increase or decrease) of protein aggregates and amyloid formation. In some embodiments, the engineered bacteriophages express anti-amyloid peptides for inhibiting protein aggregation and amyloid formation, which can be useful in the treatment and prevention of and bacterial infections and biofilms. In some embodiments, the engineered bacteriophages express amyloid peptides for promoting amyloid formation, which are useful for increasing amyloid formation such as promoting bacterial biofilms. Other aspects relate to methods to inhibit bacteria biofilms, and methods for the treatment of amyloid related disorders, e.g., Alzheimer's disease using an anti-amyloid peptide engineered bacteriophages. Other aspects of the invention relate to engineered bacteriophages to express the amyloid peptides on the bacteriophage surface and/or secrete the amyloid peptides, e.g., anti-amyloid peptides and pro-amyloid peptides, and uses thereof for modulation protein aggregates and amyloid formation. | 11-29-2012 |
20130053432 | IN VIVO GENE SENSORS - Described are methods and compositions for the detection of target genes. The inventors have developed a synthetic nucleic acid sensor-effector gene circuit. In cells without a target gene, the circuit suppresses e.g., effector production, but in the presence of the target gene the suppression is subject to competition, such that the synthetic sensor is de-repressed and permits expression of the effector gene. The methods and compositions described further permit the selective expression of an effector gene in those cells expressing the target gene. In this manner, cells expressing a target gene can be selectively targeted for treatment or elimination. In certain aspects, the methods and compositions described permit the selective expression of an agent such as a therapeutic gene product, in a specifically targeted population of cells in an organism. | 02-28-2013 |
20130122549 | RECOMBINANT PHAGE AND METHODS - This disclosure provided methods of cloning a phage genome. Also provided are methods of making a recombinant phage genome. In some embodiments the phage genome is engineered to comprise a heterologous nucleic acid sequence, for example a sequence comprising an open reading frame. In some embodiments the phage genome is cloned in a yeast artificial chromosome. Recombinant phage genomes and recombinant phage are also provided. In some embodiments the methods are high throughput methods such as methods of making a plurality of recombinant phage genomes or recombinant phage. Collections of recombinant phage genomes and recombinant phage are also provided. | 05-16-2013 |
20140315310 | RECOMBINASE-BASED LOGIC AND MEMORY SYSTEMS - The invention provides, inter alia, recombinase-based systems that provide for integrated logic and memory in living cells. | 10-23-2014 |
20150064138 | TUNING MICROBIAL POPULATIONS WITH PROGRAMMABLE NUCLEASES - Various aspects and embodiments of the invention are directed to methods and compositions for reversing antibiotic resistance or virulence in and/or destroying pathogenic microbial cells such as, for example, pathogenic bacterial cells. The methods include exposing microbial cells to a delivery vehicle with at least one nucleic acid encoding an engineered autonomously distributed circuit that contains a programmable nuclease targeted to one or multiple genes of interest. | 03-05-2015 |
20150064770 | TUNING BACTERIOPHAGE HOST RANGE - Various aspects and embodiments of the invention are directed to high-throughput phage-engineering methods and recombinant bacteriophages with tunable host ranges for controlling phage specificity. | 03-05-2015 |
20150087055 | ANALOG AND MIXED-SIGNAL COMPUTATION AND CIRCUITS IN LIVING CELLS - Provided herein are molecular analog gene circuits that exploit positive and negative feedback to implement logarithmically linear sensing, addition, subtraction, and scaling thus enabling multiplicative, ratiometric, and power-law computations. The circuits exhibit Weber's Law behavior as in natural biological systems, operate over a wide dynamic range of up to four orders of magnitude, and can be architected to have tunable transfer functions. The molecular circuits described herein can be composed together to implement higher-order functions that are well-described by both intricate biochemical models and by simple mathematical functions. The molecular circuits described herein enable logarithmically linear analog computation within in-vitro and in-vivo systems with a broad class of molecules, all of which obey the Boltzmann exponential equations of thermodynamics that govern molecular association, attenuation, transformation, and degradation. | 03-26-2015 |
Patent application number | Description | Published |
20090155215 | ENGINEERED ENZYMATICALLY ACTIVE BACTERIOPHAGE AND METHODS FOR DISPERSING BIOFILMS - The present invention is directed to engineered enzymatically active bacteriophages that are both capable of killing the bacteria by lysis and dispersing the bacterial biofilm because they have been also engineered to express biofilm-degrading enzymes, particularly dispersin B (DspB), an enzyme that hydrolyzes β-1,6-N-acetyl-D-glucosamine, a crucial adhesion molecule needed for biofilm formation and integrity in | 06-18-2009 |
20100322903 | ENGINEERED BACTERIOPHAGES AS ADJUVANTS FOR ANTIMICROBIAL AGENTS AND COMPOSITIONS AND METHODS OF USE THEREOF - The present invention relates to the treatment and prevention of bacteria and bacterial infections. In particular, the present invention relates to engineered bacteriophages used in combination with antimicrobial agents to potentiate the antimicrobial effect and bacterial killing by the antimicrobial agent. The present invention generally relates to methods and compositions comprising engineered bacteriophages and antimicrobial agents for the treatment of bacteria, and more particularly to bacteriophages comprising agents that inhibit antibiotic resistance genes and/or cell survival genes, and/or bacteriophages comprising repressors of SOS response genes or inhibitors of antimicrobial defense genes and/or expressing an agent which increases the sensitivity of bacteria to an antimicrobial agent in combination with at least one antimicrobial agent, and their use thereof. | 12-23-2010 |
20120244126 | ENGINEERED ENZYMATICALLY ACTIVE BACTERIOPHAGE AND METHODS FOR DISPERSING BIOFILMS - The present invention is directed to engineered enzymatically active bacteriophages that are both capable of killing the bacteria by lysis and dispersing the bacterial biofilm because they have been also engineered to express biofilm-degrading enzymes, particularly dispersin B (DspB), an enzyme that hydrolyzes β-1,6-N-acetyl-D-glucosamine, a crucial adhesion molecule needed for biofilm formation and integrity in | 09-27-2012 |
20140161772 | ENGINEERED ENZYMATICALLY ACTIVE BACTERIOPHAGE AND METHODS FOR DISPERSING BIOFILMS - The present invention is directed to engineered enzymatically active bacteriophages that are both capable of killing the bacteria by lysis and dispersing the bacterial biofilm because they have been also engineered to express biofilm-degrading enzymes, particularly dispersin B (DspB), an enzyme that hydrolyzes β-1,6-N-acetyl-D-glucosamine, a crucial adhesion molecule needed for biofilm formation and integrity in | 06-12-2014 |
20150050717 | BACTERIOPHAGES EXPRESSING ANTIMICROBIAL PEPTIDES AND USES THEREOF - The present invention is generally related to engineered bacteriophages expressing antimicrobial peptides or lytic enzymes or fragments thereof for targeting a broad spectrum of bacterial hosts, and for the long-term suppression of bacterial phage resistance for reducing bacterial infections. In some embodiments, bacteriophages express antimicrobial peptides or antimicrobial polypeptides (e.g. phage lytic enzymes) which are secreted from the host bacteria, or alternatively released upon lysis of the bacterial host cell. Aspects of the present invention also relate to the use of the engineered bacteriophages for the reduction of bacterial infections, both in a subject or for bioremediation purposes, in clinical settings and wound healing. | 02-19-2015 |
Patent application number | Description | Published |
20120202340 | N-TYPE DOPING OF ZINC TELLURIDE - ZnTe is implanted with a first species selected from Group III and a second species selected from Group VII. This may be performed using sequential implants, implants of the first species and second species that are at least partially simultaneous, or a molecular species comprising an atom selected from Group III and an atom selected from Group VII. The implants may be performed at an elevated temperature in one instance between 70° C. and 800° C. | 08-09-2012 |
20120288637 | METHODS OF AFFECTING MATERIAL PROPERTIES AND APPLICATIONS THEREFOR - Methods of affecting a material's properties through the implantation of ions, such as by using a plasma processing apparatus with a plasma sheath modifier. In this way, properties such as resistance to chemicals, adhesiveness, hydrophobicity, and hydrophilicity, may be affected. These methods can be applied to a variety of technologies. In some cases, ion implantation is used in the manufacture of printer heads to reduce clogging by increasing the materials hydrophobicity. In other embodiments, MEMS and NEMS devices are produced using ion implantation to change the properties of fluid channels and other structures. In addition, ion implantation can be used to affect a material's resistance to chemicals, such as acids. | 11-15-2012 |
20120289030 | ION-ASSISTED DIRECT GROWTH OF POROUS MATERIALS - Methods of creating porous materials, such as silicon, are described. In some embodiments, plasma sheath modification is used to create ion beams of various incidence angles. These ion beams may, in some cases, form a focused ion beam. The wide range of incidence angles allows the material to be deposited amorphously. The porosity and pore size can be varied by changing various process parameters. In other embodiments, porous oxides can be created by adding oxygen to previously created layers of porous material. | 11-15-2012 |
20130045339 | TECHNIQUES FOR DIAMOND NUCLEATION CONTROL FOR THIN FILM PROCESSING - Techniques for diamond nucleation control for thin film processing are disclosed. In one particular embodiment, the techniques may be realized as a method for generating a plasma having a plurality of ions; depositing a plurality of diamond nucleation centers on a substrate with the ions in the plasma using an extraction plate having at least one gap, wherein the plasma ions pass through the at least one gap in the extraction plate to generate a focused ion beam to deposit the plurality of diamond nucleation centers; and controlling the growth of a continuous diamond film from the diamond nucleation centers on the substrate by controlling at least one of a temperature around the substrate, a temperature of the plasma, a pressure around the substrate, and a concentration of the ions in the plasma. | 02-21-2013 |
20130045557 | DEPOSITION OF POROUS FILMS FOR THERMOELECTRIC APPLICATIONS - An improved method of creating thermoelectric materials which have high electrical conductivity and low thermal conductivity is disclosed. In one embodiment, the thermoelectric material is made by depositing a porous film onto a substrate, introducing a dopant into the porous film and annealing the porous film to activate the dopant. In other embodiments, additional amounts of dopant may be introduced via subsequent ion implantations of dopant into the deposited porous film. | 02-21-2013 |
20130189579 | Material Engineering for High Performance Li-ion Battery Electrodes - A method of treating an electrode for a battery to enhance its performance is disclosed. By depositing a layer of porous carbon onto the electrode, its charging and discharging characteristics, as well as chemical stability may be improved. The method includes creating a plasma that includes carbon and attracting the plasma toward the electrode, such as by biasing a platen on which the electrode is disposed. In some embodiments, an etching process is also performed on the deposited porous carbon to increase its surface area. The electrode may also be exposed to a hydrophilic treatment to improve its interaction with the electrolyte. In addition, a battery which includes at least one electrode treated according to this process is disclosed. | 07-25-2013 |
20140038393 | METHOD AND SYSTEM FOR ION-ASSISTED PROCESSING - A method of processing a substrate includes performing a first exposure that comprises generating a plasma containing reactive gas ions in a plasma chamber and generating a bias voltage between the substrate and the plasma chamber. The method also includes providing a plasma sheath modifier having an aperture disposed between the plasma and substrate and operable to direct the reactive gas ions toward the substrate, and establishing a pressure differential between the plasma chamber and substrate region while the reactive gas ions are directed onto the substrate. | 02-06-2014 |
20140256121 | TECHNIQUES AND APPARATUS FOR HIGH RATE HYDROGEN IMPLANTATION AND CO-IMPLANTION - An apparatus for hydrogen and helium implantation is disclosed. The apparatus includes a plasma source system to generate helium ions and hydrogen molecular ions comprising H | 09-11-2014 |
Patent application number | Description | Published |
20090172319 | SYSTEMS AND METHODS FOR RECOVERING ELECTRONIC INFORMATION FROM A STORAGE MEDIUM - In one embodiment of the invention, a method is provided for retrieving certain electronic information previously stored on certain storage media after a threshold set in the storage retention criteria has been exceeded in an electronic information storage system that stores electronic information on storage media in accordance with a storage retention criteria is provided. The method includes storing a record in a memory associated with a system manager that assigns the storage retention criteria to the certain electronic data, designating the storage media available for overwrite after the threshold set in the storage retention policy has been exceeded, identifying the certain storage media available for overwrite, and retrieving information from the certain media after the threshold set in the storage retention policy has been exceeded. | 07-02-2009 |
20110093672 | SYSTEMS AND METHODS FOR RECOVERING ELECTRONIC INFORMATION FROM A STORAGE MEDIUM - In one embodiment of the invention, a method is provided for retrieving certain electronic information previously stored on certain storage media after a threshold set in the storage retention criteria has been exceeded in an electronic information storage system that stores electronic information on storage media in accordance with a storage retention criteria is provided. The method includes storing a record in a memory associated with a system manager that assigns the storage retention criteria to the certain electronic data, designating the storage media available for overwrite after the threshold set in the storage retention policy has been exceeded, identifying the certain storage media available for overwrite, and retrieving information from the certain media after the threshold set in the storage retention policy has been exceeded. | 04-21-2011 |
20120185657 | SYSTEMS AND METHODS FOR RECOVERING ELECTRONIC INFORMATION FROM A STORAGE MEDIUM - In one embodiment of the invention, a method is provided for retrieving certain electronic information previously stored on certain storage media after a threshold set in the storage retention criteria has been exceeded in an electronic information storage system that stores electronic information on storage media in accordance with a storage retention criteria is provided. The method includes storing a record in a memory associated with a system manager that assigns the storage retention criteria to the certain electronic data, designating the storage media available for overwrite after the threshold set in the storage retention policy has been exceeded, identifying the certain storage media available for overwrite, and retrieving information from the certain media after the threshold set in the storage retention policy has been exceeded. | 07-19-2012 |
20130275380 | SYSTEM AND METHOD FOR EXTENDED MEDIA RETENTION - The present invention provides systems and methods for extending media retention. Methods are provided in which a set of aging preferences are obtained. Data elements of a data set stored on storage media are evaluated against the aging preferences to determine whether each of the data elements satisfy the aging preferences. Each of the data elements that is determined to satisfy the aging preferences is aged. Aging can include freeing a portion of storage media, previously used to store a data element, for other storage usage. | 10-17-2013 |
Patent application number | Description | Published |
20120315274 | Methods of Treating Glucose Metabolism Disorders - Methods of treating individuals with a glucose metabolism disorder such as diabetes, hyperglycemia, hyperinsulinemia or obesity by administering human FAM3D (family with sequence similarity 3, member D) are provided. Specifically a method of treating hyperglycemia resulting in a reduction of plasma glucose is provided. Additionally, a method of treating hyperinsulinemia resulting in a reduction of plasma glucose is provided. In addition, a method of treating glucose intolerance resulting in an increased glucose tolerance is provided. Pharmaceutical compositions are provided. | 12-13-2012 |
20130017994 | Methods of Treating Glucose Metabolism Disorders - Methods of treating individuals with a glucose metabolism disorder, and compositions thereof, are provided. | 01-17-2013 |
20130071391 | Methods of Treating Glucose Metabolism Disorders - Methods of treating individuals with a glucose metabolism disorder, and compositions thereof, are provided. | 03-21-2013 |
20130130975 | Methods of Treating Glucose Metabolism Disorders - Methods of treating individuals with a glucose metabolism disorder, and compositions thereof, are provided. | 05-23-2013 |
20130136738 | Methods of Treating Glucose Metabolism Disorders - Methods of treating individuals with a glucose metabolism disorder, and compositions thereof, are provided. | 05-30-2013 |
20130216537 | Methods of Treating Glucose Metabolism Disorders and Promoting Weight Loss - Compositions and methods for treating individuals with a glucose metabolism disorder and methods for promoting weight loss in an individual are provided. | 08-22-2013 |
20130216546 | Methods of Treating Glucose Metabolism Disorders - Methods of treating individuals with a glucose metabolism disorder, and compositions suitable for use in the methods, are provided. | 08-22-2013 |
Patent application number | Description | Published |
20100311105 | METHODS OF DELIVERY OF EXOGENOUS PROTEINS TO THE CYTOSOL AND USES THEREOF - The present invention is directed to a method for delivering exogenous proteins to the cytosol, by binding a target antigen (such as a protein) to a transport factor that contains a fragment of a bipartite protein exotoxin, but not the corresponding protective antigen. Preferably, the target antigen is fused to the transport factor. Preferred transport factors include the protective antigen binding domain of lethal factor (LFn) from | 12-09-2010 |
20120148621 | METHODS AND COMPOSITIONS FOR PROMOTING A CELL-MEDIATED IMMUNE RESPONSE - The present invention is directed to a method for promoting or stimulating a cell-mediated immune response to an antigen, by administering a target antigen (such as a protein) with a transport factor that contains a fragment of a bipartite protein exotoxin, but not the corresponding protective antigen. Preferred transport factors include the protective antigen binding domain of lethal factor (LFn) from | 06-14-2012 |
20120172254 | METHODS AND COMPOSITIONS FOR DIAGNOSTIC ASSAYS FOR MEASURING CELL MEDIATED IMMUNE RESPONSE - Described are compositions and methods for detecting or monitoring the ability of an individual to mount a cell mediated immune response to a target antigen. Methods rely in part upon the physical association, e.g., by fusion, of a Lethal Factor (LF) polypeptide with a target antigen. The LF polypeptide moiety, including, for example, an LFn polypeptide moiety, serves as a transport factor to deliver target antigens, including full length target polypeptides, to the cytosol of an intact, living immune cell from an individual. Measurement of a cytokine response by the immune cell from the individual provides a read out of a cell cell from mediated immune response. The methods and compositions described provide diagnostic as well as prognostic information and can guide the direction of therapy. | 07-05-2012 |
20130115237 | THERAPEUTIC IMMUNIZATION IN HIV INFECTED SUBJECTS TO AUGMENT ANTIRETROVIRAL TREATMENT - The present invention generally relates to HIV compositions and methods of use. One aspect of the present invention relates to a composition comprising a pharmaceutically acceptable carrier and an antigen preparation, the antigen preparation comprising an HIV polypeptide or fragment thereof and a | 05-09-2013 |
Patent application number | Description | Published |
20120251577 | SELECTIVELY DISRUPTED WHOLE-CELL VACCINE - The present invention provides for immunogenic compositions and methods for producing an immunogenic composition with multiple immunity-inducing fractions of killed, whole-cell | 10-04-2012 |
20130039947 | NOVEL IMMUNOGENS AND METHODS FOR DISCOVERY AND SCREENING THEREOF - The present application is generally directed to methods for identifying immunogens from organisms and pathogens, and in particular for identifying immunogens which when administered as vaccines elicit a cellular and/or humoral immune response. The present application is also directed to pneumococcal T-cell immunogens, and vaccine compositions comprising one or a combination of pneumococcal immunogens and methods for treating or preventing pneumococcal infections using the vaccines thereof. The present invention also encompasses use of the pneumococcal immunogens for diagnostic purposes to identify a subject with a pneumococcal infection. | 02-14-2013 |
20140154286 | MODIFIED BIOTIN-BINDING PROTEIN, FUSION PROTEINS THEREOF AND APPLICATIONS - The disclosure provides modified biotin-binding proteins which can be expressed in soluble form in high yield in bacteria. Also provided are fusion proteins comprising the modified biotin-binding protein and an antigen. The disclosure further provides non-hemolytic variants of alpha-hemolysin from | 06-05-2014 |
20140154287 | MULTIPLE ANTIGEN PRESENTING IMMUNOGENIC COMPOSITION, AND METHODS AND USES THEREOF - The present embodiments provide for an immunogenic multiple antigen presenting system comprising a polymer to which antigens are associated by complementary affinity molecules. For example, the polymer can be a polysaccharide, or antigenic polysaccharide, to which protein or peptide antigens from the same or different pathogens are indirectly linked. The present immunogenic compositions can elicit both humoral and cellular immune responses to one or multiple antigens at the same time. | 06-05-2014 |
Patent application number | Description | Published |
20100105653 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES - The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein. | 04-29-2010 |
20110152244 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES - The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein. | 06-23-2011 |
Patent application number | Description | Published |
20120150123 | INFUSION SET - A single package infusion set is provided, including one or more of the following inserters: pushbutton-type, squeeze-type, contact-type, skin pinching-type, folding retraction-type, or multistage-type inserter having at least one reusable stage. The infusion set further includes adhesion means with user-selectable degrees of adhesion strength, self-sealing tube connection means, a lens feature to view, a site beneath the set, exemplary tube management and connection elements, insulin supply, adhesion concealment means, finger loops on the inserter and site preparation wipes or sprays, optionally provided as part of the inserter. The system further includes a package which may hold a number of easily released sets, retrievable by an inserter, an exemplary insertion needle handle and shroud, an exemplary squeeze-type latch between an upper portion and a lower portion of the set, and/or a tool removable upper portion of the set. | 06-14-2012 |
Patent application number | Description | Published |
20120030060 | DETERMINING A LIKELIHOOD OF SUITABILITY BASED ON HISTORICAL DATA - Some embodiments of the invention determine whether a particular item is likely to suit a consumer from a fit and/or style standpoint, using objective data produced as a result of the consumer's experiences. For example, some embodiments of the invention analyze information regarding a consumer's experiences with certain products (e.g., purchase and return history, identification of “favorite” items, etc.) and data regarding attributes of those items (e.g., technical dimension data, stylistic and fit attributes, etc.) to determine the consumer's measurements and fit and/or style preferences, so that a prediction may be made regarding how a particular size of an item may suit the consumer. | 02-02-2012 |
20120030061 | FIT RECOMMENDATION VIA COLLABORATIVE INFERENCE - Some embodiments of the invention provide techniques for recommending a size of a subject item to fit a subject consumer. In some embodiments, clusters of consumers with fit characteristics similar to the subject consumer are identified, using one or more data clustering algorithms, based on any of numerous consumer attributes (e.g., self-reported and/or inferred height, weight, body shape, body characteristics, and/or purchase histories (e.g., consumers with high overlap in terms of sets of products purchased)). Information on other consumers in the cluster may be analyzed to draw conclusions on how different sizes of the subject item may fit the subject consumer. For example, the purchase history of other members of the cluster may be analyzed to determine whether other members purchased a particular size of the item, and if so, the size purchased by the other members may serve as a basis to recommend a size that may best fit the consumer. For example, if other members of the cluster purchased a particular size, then that size may be recommended to the subject consumer, or if other members of the cluster purchased and then returned a particular size (e.g., for being too small), then another (e.g., larger) size may be recommended to the subject consumer. | 02-02-2012 |
20130268399 | FIT RECOMMENDATION VIA COLLABORATIVE INFERENCE - Some embodiments of the invention provide techniques for recommending a size of a subject item to fit a subject consumer. In some embodiments, clusters of consumers with fit characteristics similar to the subject consumer are identified, using one or more data clustering algorithms, based on any of numerous consumer attributes (e.g., self-reported and/or inferred height, weight, body shape, body characteristics, and/or purchase histories (e.g., consumers with high overlap in terms of sets of products purchased)). Information on other consumers in the cluster may be analyzed to draw conclusions on how different sizes of the subject item may fit the subject consumer. For example, the purchase history of other members of the cluster may be analyzed to determine whether other members purchased a particular size of the item, and if so, the size purchased by the other members may serve as a basis to recommend a size that may best fit the consumer. For example, if other members of the cluster purchased a particular size, then that size may be recommended to the subject consumer, or if other members of the cluster purchased and then returned a particular size (e.g., for being too small), then another (e.g., larger) size may be recommended to the subject consumer. | 10-10-2013 |